Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Long-Term Debt Repayments (2018 - 2023)

Ligand Pharmaceuticals (LGNDZ) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $76.9 million as the latest value for Q2 2023.

  • Quarterly Long-Term Debt Repayments rose 28.2% to $76.9 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $76.9 million through Sep 2024, changed 0.0% year-over-year, with the annual reading at $76.9 million for FY2023, 70.55% down from the prior year.
  • Long-Term Debt Repayments hit $76.9 million in Q2 2023 for Ligand Pharmaceuticals, up from $37.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $203.2 million in Q1 2020 to a low of $2.4 million in Q3 2021.
  • Historically, Long-Term Debt Repayments has averaged $74.3 million across 5 years, with a median of $52.3 million in 2021.
  • Biggest five-year swings in Long-Term Debt Repayments: plummeted 46.45% in 2021 and later surged 1482.43% in 2022.
  • Year by year, Long-Term Debt Repayments stood at $27.3 million in 2019, then plummeted by 30.47% to $19.0 million in 2020, then plummeted by 87.48% to $2.4 million in 2021, then soared by 1482.43% to $37.6 million in 2022, then surged by 104.15% to $76.9 million in 2023.
  • Business Quant data shows Long-Term Debt Repayments for LGNDZ at $76.9 million in Q2 2023, $37.6 million in Q3 2022, and $59.9 million in Q2 2022.